24/7 Wall St. on MSN1h
The Magnificent 7 Blue-Chip Dividend Stocks to Buy in 2025 and Hold Forever
These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.
Peninsula biotech to lay off 40% of workforce as it restructures
Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce to help extend its cash into second-quarter 2026, ...
FiercePharma4d
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version
Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Pharmaceutical Technology1d
BMS-986484 by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.
Baylor College of Medicine11h
Baylor College of Medicine
Texas Children’s Global HOPE and Baylor College of Medicine Global Health, with support from the Bristol Myers Squibb Foundation, an independent charitable organization, announced the next front in ...